Santhera Revenue Doubles to CHF 48.3M, Confirms CHF 80-90M 2026 Guidance

Santhera Pharmaceuticals (SIX: SANN) reported on 30 September 2026 that total revenue for the six months ended 30 June 2026 rose 101% to CHF 48.3 million, from CHF 24.0 million a year earlier. Product sales grew 48% to CHF 17.2 million. The Swiss rare-disease company kept its full-year 2026 revenue guidance at CHF 80–90 million and said its cash profile will not require additional funding.

Context — Why Santhera's AGAMREE Access Expansion Matters Now

Santhera's half-year numbers are the first since AGAMREE (vamorolone) crossed from a two-market European launch into a five-market race. A year ago the company reported revenue of CHF 24.0 million and an operating loss of CHF 35.4 million. The comparable period now shows an operating loss of CHF 6.6 million, a narrowing of CHF 28.8 million.

The swing is not organic alone. In January 2026, Santhera signed an exclusive licensing agreement with Nxera Pharma covering Japan, South Korea, Australia and New Zealand, valued at up to USD 215 million plus royalties. That deal carried a USD 40 million upfront, split between USD 30 million cash and a USD 10 million equity investment at a 20% premium to the 30-day VWAP prior to the announcement day.

The trigger for the equity story is access, not price. Pricing and reimbursement agreements in Spain and Italy during the first half mean AGAMREE is commercially available in four of the five major EU markets, adding to Germany and the UK. The company said German volumes rose more than 50% year over year in H1 2026, and UK orders climbed more than 40% quarter over quarter in Q2.

Macro conditions are secondary here. Santhera is a single-asset specialty pharma with a Swiss listing, so its re-rating depends on reimbursement wins and partner sales, not on the rate cycle.

Data — What the Numbers Show

The revenue mix moved sharply. Royalties and milestones rose to CHF 29.1 million from CHF 6.5 million, with the company attributing most of that to the USD 30 million (CHF 24.2 million) Nxera cash upfront. Revenue from supplying products and services to partners fell, as expected, to CHF 2.1 million from CHF 5.9 million, which the company tied to Catalyst's transition to direct sourcing.

Metric	H1 2026	H1 2025
Total revenue	CHF 48.3m	CHF 24.0m
Product sales	CHF 17.2m	CHF 11.6m
Royalties and milestones	CHF 29.1m	CHF 6.5m
Partner supply revenue	CHF 2.1m	CHF 5.9m
Operating expenses	CHF 25.0m	CHF 27.3m
Operating loss	CHF 6.6m	CHF 35.4m
Cash and equivalents	CHF 41.8m	CHF 22.4m

Operating expenses fell 8.4% to CHF 25.0 million, which the company credited to lower development costs. Cash and cash equivalents rose to CHF 41.8 million at 30 June 2026 from CHF 22.4 million at 31 December 2025.

Global AGAMREE sales, including partner sales, exceeded USD 175 million on a four-consecutive-quarter basis in Q2 2026. That triggered a USD 20 million (CHF 16.3 million) sales milestone payment obligation, which Santhera recognized in cost of sales. The company did not disclose the counterparty to that obligation.

The German price per bottle fell to EUR 3,001 in January 2026 from EUR 3,612, which the company described as a one-time, pre-agreed adjustment at the time of initial pricing and reimbursement in early 2025.

Analysis — What It Means for Pharma and Rare-Disease Tickers

The second-order read is that Santhera's revenue quality is shifting from product to licensing. Product sales of CHF 17.2 million are roughly a third of total revenue, while the Nxera upfront alone is CHF 24.2 million. Strip out the deal and H1 revenue looks far closer to the prior year. That matters for anyone modelling recurring cash flow.

Partner economics are the second lever. Catalyst Pharmaceuticals reported AGAMREE net product revenue of USD 36.7 million in Q1 2026, against USD 22.0 million in Q1 2025, and had guided to FY 2026 AGAMREE net product revenue of USD 140–150 million before Angelini Pharma S.p.A. agreed to acquire it for approximately USD 4.1 billion. The transaction completed on 16 July 2026. Santhera expects no further North American product sales from Q1 2026 onward, but keeps royalties, potential milestones and service payments.

China is the wildcard. Partner Sperogenix has treated more than 1000 patients to date, and Santhera said product sales to Sperogenix should be significantly higher in the second half following a larger Q3 batch shipment. The company is also in technology-transfer discussions that could enable local manufacturing from 2028.

The counter-argument sits in France. Santhera said the French reimbursement process will take longer and needs a full resubmission, with no commercial launch currently expected before 2028. That leaves one of Europe's largest DMD markets effectively closed for at least two years, and it caps the addressable European revenue base regardless of how the other four markets perform.

Positioning follows the data. The stock is a reimbursement-event trade rather than a volume-momentum trade, and the flow that matters is whether milestone triggers keep firing ahead of the modelled dates.

Outlook — What to Watch Next

Three catalysts carry the second half. First, the Q3 shipment to Sperogenix converts the company's own guidance into reported product sales, and H2 product revenue is where the more than 50% full-year product growth target gets tested. Second, AGAMREE's EU authorization extension to patients from two years of age, following the positive CHMP opinion adopted in April 2026, widens the prescriber base. Third, Nxera has indicated it plans to file for Japanese regulatory approval in the second half of 2027.

The cash path is the item to track. Santhera said cash should stay broadly stable at 30 September levels through year-end, then decline in H1 2027 as inventory purchases move into Q1 2027 and a mandatory German price reduction takes effect from Q1 2027. The company expects to return to cash generation in the second half of 2027 and stated this profile will not require additional funding.

No price levels or moving averages were disclosed in the report.

Frequently Asked Questions

What does Santhera's H1 2026 result mean for retail investors?

It means the loss narrowed without new equity. Operating loss fell to CHF 6.6 million from CHF 35.4 million, and cash rose to CHF 41.8 million from CHF 22.4 million at year-end 2025. The company also reaffirmed that its H1 2027 cash decline will not require additional funding. The open question is how much of the revenue base is repeatable once the Nxera upfront drops out of the comparison.

Why did Santhera's royalties and milestones jump to CHF 29.1 million?

The increase came almost entirely from a single licensing event. The Nxera agreement's USD 30 million cash upfront converted to CHF 24.2 million and was recognized in the period. The prior-year figure of CHF 6.5 million had no comparable upfront. A separate USD 20 million milestone obligation was triggered by global AGAMREE sales exceeding USD 175 million on a four-quarter basis, but that was booked in cost of sales, not revenue.

What happens next for AGAMREE in France and other unreimbursed markets?

Santhera said the French process requires a full resubmission and that a commercial launch is not currently expected before 2028, though it is exploring faster access routes. In Luxembourg, pricing and reimbursement was agreed in August 2026, the first Benelux market to secure it. The company continues talks across the other Benelux countries, the Nordics, Portugal, Switzerland and Ireland.

Bottom Line

Santhera doubled revenue on one licensing payment, and the H1 2027 cash dip now tests whether product sales can stand alone.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.